EGFR and breast cancer: The level of mir-155-3p is upregulated in breast cancer cells.471 GSDME is the direct binding target of mir-155-5p.472 Cetuximab combined with mir-155-5p antagomir can promote the pyroposis of EGFR overexpressed breast cancer cells, induce apoptosis, enhance the antitumor effect of cetuximab, and provide an alternative treatment for breast cancer patients by upregulating GSDME-N and cleaved caspase-1.472 Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world.